Drug details

Kesimpta (ofatumumab injection)

type of Neurologics Anti-CD20 Monoclonal Antibodies

Kesimpta (ofatumumab) is a CD20-directed cytolytic antibody used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

This drug may have the following side effects:

• upper respiratory tract infection,
• headache,
• injection-related reactions (fever, headache, muscle pain, chills, and fatigue), and
• local injection site reactions (redness, pain, itching, and swelling)

The following drugs are related to Kesimpta, either as a replacement or used together:

• Lemtrada (alemtuzumab injection for intravenous infusion)
• Ampyra (dalfampridine extended-release tablets)
• Aubagio (teriflunomide tablets)
• Imuran (azathioprine)
• Lyvispah (baclofen oral granules)
• Fleqsuvy (baclofen oral suspension)
• Briumvi (ublituximab-xiiy injection)
• Mavenclad (cladribine tablets)
• Dxevo (dexamethasone tablets)
• Tecfidera (dimethyl fumarate delayed release capsules)
• Vumerity (diroximel fumarate delayed-release capsules)
• Extavia (interferon beta-1b kit)
• Tascenso ODT (fingolimod orally disintegrating tablets)
• Glatopa (glatiramer acetate injection)
• Rebif (interferon beta-1a)
• Mayzent (siponimod tablets)
• Tysabri (natalizumab)
• Tyruko (natalizumab-sztn injection)
• Ocrevus (ocrelizumab injection)
• Zeposia (ozanimod capsules)
• Plegridy (peginterferon beta-1a injection for subcutaneous use)
• Ponvory (ponesimod tablets)